Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of in Vivo Expansion of Melan-A/MART-1 Antigen-Specific CD8 T Lymphocytes Following Transient Immunosuppression in Patients With Advanced Melanoma

NCT00160992 is registered in ClinicalTrials.gov with University of Lausanne Hospitals as lead sponsor.

NCT NCT00160992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00160992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of in Vivo Expansion of Melan-A/MART-1 Antigen-Specific CD8 T Lymphocytes Following Transient Immunosuppression in Patients With Advanced Melanoma
Lead sponsor
University of Lausanne Hospitals
Phase
Phase 1
Overall status
Suspended
Start date
July 31, 2004
Completion date
August 31, 2005
Enrollment
6
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma